Amyotrophic lateral sclerosis (ALS) is a devastating adult-onset neurodegenerative disease that wreaks havoc on motor neurons. A progressive and fatal muscle paralysis ensues, causing death within 2 to 5 years. Recently, a central role for RNA binding proteins and RNA metabolism pathways has emerged. The protein TDP-43 was recently identified as the major disease protein in pathological inclusions in both ALS and frontal temporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U). Moreover, mutations in the TDP-43 gene have now been identified in sporadic and familial ALS patients. Pathology and genetics both converge on TDP-43 being central to the pathogenesis of these diseases. In the first five years of this research project, we have generated in vitro and in vivo TDP-43 proteinopathy models to explore TDP-43. We have harnessed the simple yeast model system to study TDP-43's properties and the effect of ALS-linked mutations. Our preliminary data demonstrate: 1) a critical role for the RNA recognition motif and carboxy-terminal region of TDP-43 in mediating aggregation and cellular toxicity, 2) increased aggregation and toxicity caused by a disease-linked TDP-43 mutation, and 3) genetic screens identified multiple RNA binding proteins as potent toxicity modifiers. One of these, Pbp1, is the yeast homolog of human ataxin 2 and we identified polyglutamine expansions in ataxin 2 as a major genetic risk factor for ALS in humans. We also discovered that deletion of the Dbr1 gene potently suppresses TDP-43 toxicity. The identification of a major genetic risk factor for ALS in humans and a novel and unexpected therapeutic target for ALS starting from the simple yeast model, illustrates the power of this approach. We have also pursued studies beyond TDP-43, focusing on additional RNA-binding proteins, such as FUS, TAF15, EWSR1, and several more. We have discovered a prion-like domain in TDP-43 and FUS and have used this domain to link additional RNA-binding proteins to a class of proteins with similar structural and functional properties. For the next five years of this project, with the goal to define TDP-43 disease mechanisms from multiple angles we propose three Specific Aims: 1) Continuing to characterize hits from our yeast TDP-43 toxicity modifier screens to elucidate additional mechanisms of TDP- 43 toxicity and to perform an additional yeast screen of ~1,000 essential genes;2) Defining the mechanism by which Dbr1 inhibition suppresses TDP-43 toxicity and extending these studies to mammalian cells and animal models;3) Testing the hypothesis that aggregation-prone RNA-binding proteins contribute broadly to ALS using next generation sequencing approaches.
As our population continues to age, neurodegenerative disease will increase in prevalence and thus pose a daunting challenge to public health worldwide. The protein TDP-43 has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontal temporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U), but very little is known about the mechanisms by which TDP-43 causes neurodegeneration. Our project harnesses multiple in vitro and in vivo models and techniques to gain mechanistic insight into how TDP-43 contributes to human disease, which will suggest novel avenues for therapeutic intervention.
|Couthouis, Julien; Raphael, Alya R; Siskind, Carly et al. (2014) Exome sequencing identifies a DNAJB6 mutation in a family with dominantly-inherited limb-girdle muscular dystrophy. Neuromuscul Disord 24:431-5|
|Figley, Matthew D; Bieri, Gregor; Kolaitis, Regina-Maria et al. (2014) Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics. J Neurosci 34:8083-97|
|Figley, Matthew D; Thomas, Anna; Gitler, Aaron D (2014) Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis. Neurobiol Aging 35:936.e1-4|
|Jovi?i?, Ana; Gitler, Aaron D (2014) TDP-43 in ALS: stay on target…almost there. Neuron 81:463-5|
|Raphael, Alya R; Couthouis, Julien; Sakamuri, Sarada et al. (2014) Congenital muscular dystrophy and generalized epilepsy caused by GMPPB mutations. Brain Res 1575:66-71|
|Couthouis, Julien; Raphael, Alya R; Daneshjou, Roxana et al. (2014) Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet 10:e1004704|
|Kim, Hyung-Jun; Raphael, Alya R; LaDow, Eva S et al. (2014) Therapeutic modulation of eIF2? phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet 46:152-60|
|Aguzzi, Adriano; Gitler, Aaron D (2013) A template for new drugs against Alzheimer's disease. Cell 154:1182-4|
|Li, Yun R; King, Oliver D; Shorter, James et al. (2013) Stress granules as crucibles of ALS pathogenesis. J Cell Biol 201:361-72|
|Chesi, Alessandra; Staahl, Brett T; Jovicic, Ana et al. (2013) Exome sequencing to identify de novo mutations in sporadic ALS trios. Nat Neurosci 16:851-5|
Showing the most recent 10 out of 24 publications